ARTICLE | Clinical News
VLA15-101: Ph I started
December 13, 2016 10:11 PM UTC
Valneva began a single-blind, dose-escalation, international Phase I trial to evaluate VLA15-101 in about 180 healthy volunteers....
BCIQ Company Profiles
BCIQ Target Profiles